Humanin
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A 24-amino-acid peptide encoded by mitochondrial DNA, marketed for neuroprotection, metabolic support, and longevity. The evidence is almost entirely cell and animal work; there are no controlled human trials and essentially no human safety data. Its anti-apoptotic, STAT3-driven mechanism raises an unresolved concern about promoting existing cancers. Not an approved drug in the US, and supply is unregulated research-grade material of uncertain purity.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Humanin is a small 24-amino-acid peptide naturally produced by your mitochondria (the energy-producing structures inside every cell). Discovered in 2001 from the brain tissue of an Alzheimer's patient, it was the first peptide found to be encoded by mitochondrial DNA — a discovery that opened an entirely new field of biology. Named to reflect its potential to 'restore humanity' in Alzheimer's patients, humanin is a powerful cell-protective factor found in the heart, kidneys, liver, brain, and skeletal muscle. Its levels decline with age in mice, monkeys, and humans, but remain significantly elevated in centenarians and their children, suggesting a direct link to longevity.
How it works in the body
A 24-amino-acid peptide encoded by mitochondrial DNA. It binds to the FPRL1 receptor and a trimeric receptor complex (CNTFR/WSX-1/gp130), activating STAT3 and ERK survival pathways. This protects cells — especially neurons — from programmed cell death triggered by amyloid-beta, oxidative stress, and other insults.
Research overview
Humanin is one of the most extensively studied mitochondrial-derived peptides, with over two decades of research across neuroprotection, metabolic health, cardiovascular protection, and aging biology. It works through multiple mechanisms: inside cells, it blocks programmed cell death, activates cellular cleanup processes, and reduces damaging free radicals; outside cells, it activates survival signaling pathways through specific receptors. Notably, humanin can directly interact with Alzheimer's-related amyloid proteins and convert them from toxic clumps into harmless forms. In worm models, boosting humanin extended lifespan. In mice, its potent synthetic analog HNG (1,000 times more active) improved memory in Alzheimer's models, reduced fat, and increased lean body mass in aged animals. All evidence comes from cell culture and animal studies — no human clinical trials have been completed as of early 2026.
Who researches Humanin?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Active cancer
ModerateHumanin is anti-apoptotic — helps cells resist programmed death. May protect cancer cells from apoptosis in some contexts.
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data. Anti-apoptotic effects during fetal development are unpredictable.
Safety & interactions
Do not use if
Active cancer
ModerateHumanin is anti-apoptotic — helps cells resist programmed death. May protect cancer cells from apoptosis in some contexts.
General cautions
Pregnancy
AbsoluteNo human reproductive safety data. Anti-apoptotic effects during fetal development are unpredictable.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
No controlled human clinical trials; all safety from preclinical
HighPMC10135985 (systematic review); AJP-Endo 2020, doi:10.1152/ajpendo.00249.2020
Anti-apoptotic mechanism (Bax inhibition) may facilitate tumor progression in some cancers
ModerateNature Sci Rep 2020, PMC7244539 / s41598-020-65381-7
Signals through STAT3, implicated in cancer progression
ModeratePMC7244539 (TNBC/STAT3); PMC10135985 (STAT3 receptor signaling)
Transgenic humanin mice showed 46.5% decrease in litter size
LowPMC7343442 / Aging 2020, article 103534
Transgenic humanin mice showed 12% decrease in body length / 10.4% lower body weight
LowPMC7343442 / Aging 2020, article 103534
Injection site irritation (community reports)
LowAnecdotal community reports; no peer-reviewed source located
Interaction summary(5)
Rated by direction with this peptide
Cytotoxic chemotherapy (antitumor efficacy) - e.g. doxorubicin, paclitaxel, cisplatin
CautionModerateIn TNBC-bearing mice, systemic humanin blunted chemotherapy's antitumor and anti-metastatic effect and accelerated tumor progression, so concurrent use in active cancer could protect tumor cells and reduce chemo efficacy. In-vivo demonstrated; human relevance not quantified.
Nature Sci Rep 2020, PMC7244539
Chemotherapy-induced organ & germ-cell toxicity (cyclophosphamide, doxorubicin, cisplatin)
ProtectiveLowOpposite context to tumor cells: humanin/analogs reduced cyclophosphamide- and doxorubicin-induced male germ-cell apoptosis and preserved cardiomyocyte mitochondrial integrity, i.e. protected normal tissue from chemo toxicity in preclinical models. Primary support is the peer-reviewed Apoptosis 2015 germ-cell study; the cited US Patent 10792331 is non-peer-reviewed and treated as weak, corroborating-only.
Apoptosis 2015, doi:10.1007/s10495-015-1105-5 (primary); US Patent 10792331 (non-peer-reviewed, corroborating only)
Insulin / sulfonylureas / other glucose-lowering agents
SynergisticTheoreticalPreclinically humanin enhances insulin sensitivity, increases glucose uptake and suppresses hepatic glucose output, so it could add to glucose-lowering drugs; additive hypoglycemia in humans is unstudied but warrants monitoring (treat the same-direction effect as a hypoglycemia caution).
PMC4873641; Frontiers Endocrinol 2021, doi:10.3389/fendo.2021.808120
Growth hormone / IGF-1 therapy
CautionLowHumanin and IGF-1 reciprocally suppress each other (IGF-1 lowers plasma humanin and humanin lowers circulating IGF-1; inverse correlation in humans), so co-use may mutually blunt effects and humanin may oppose GH/IGF-1 anabolic signaling.
PMC4172517 (IGF-I regulates humanin); PMC4961574 (humanin-IGF-I interfaces)
Metformin
SynergisticTheoreticalIndirect and unproven (two-step inference): metformin lowers IGF-1, and IGF-1 suppresses humanin, so metformin could plausibly raise endogenous humanin; the metabolic and anti-aging directions align, but no direct metformin-humanin interaction study exists.
PMC4172517 (humanin-IGF-1 axis); metformin-IGF-1 meta-analysis, doi:10.1016/j.mad.2019.111143
Known risks(8)
Potential tumor promotion
Humanin's anti-apoptotic mechanism (Bax inhibition) may facilitate tumor progression in certain cancers. Studies have observed pro-tumoral effects in triple-negative breast cancer, glioblastoma, and gastric cancer models. Suppressing humanin increased tumor apoptosis and reduced growth in these models.
No human safety data
No controlled human clinical trials have been conducted. All safety information is derived from animal studies and anecdotal community reports. Long-term effects of exogenous humanin administration are unknown.
STAT3-mediated oncogenic potential
Humanin signals through STAT3, a pathway implicated in cancer progression. Long-term exogenous administration could theoretically promote oncogenic signaling, though this has not been systematically studied.
Reproductive effects
Transgenic humanin mice showed 46.5% decrease in litter size, suggesting potential effects on fertility or reproductive function.
Growth and development effects
Transgenic humanin mice exhibited 12% decrease in body length and 10.4% reduction in body weight, suggesting potential effects on growth hormone/IGF-1 axis.
Injection site reactions
Community reports indicate mild redness, swelling, and skin irritation at injection sites, described as short-lived.
Gastrointestinal symptoms
Rare occurrences of nausea, vomiting, and mild diarrhea reported, typically limited to the first dose and resolving within hours.
Unstable peptide
Humanin has stability challenges requiring specialized formulations (e.g., monoolein-based formulations) to maintain structure at physiological temperatures. Degradation products and their effects are not characterized.
Drug interactions(6)
IGF-1 / Growth Hormone axis modulators
Theoretical/ModerateHumanin binds IGFBP-3 (insulin-like growth factor binding protein 3), preventing caspase activation. Concurrent use with GH or IGF-1 therapies may alter humanin's signaling dynamics and IGFBP-3 availability.
Chemotherapy agents (e.g., cyclophosphamide)
Theoretical/HighHumanin protects germ cells and lymphocytes from chemotherapy-induced apoptosis. While this could be beneficial for preserving healthy tissue, it could theoretically reduce chemotherapy efficacy against tumors by inhibiting Bax-mediated apoptosis in cancer cells.
Anti-cancer therapies targeting apoptosis
Theoretical/HighHumanin's Bax-inhibiting, anti-apoptotic mechanism directly opposes the mechanism of pro-apoptotic cancer therapies (e.g., BH3 mimetics like venetoclax). Concurrent use could reduce therapeutic efficacy.
JAK/STAT pathway inhibitors (e.g., tofacitinib, ruxolitinib)
Theoretical/ModerateHumanin signals through STAT3 via the gp130 receptor complex. JAK/STAT inhibitors may attenuate humanin's cytoprotective signaling.
Insulin and diabetes medications
Theoretical/Low-ModerateHumanin interacts with the insulin/IGF-1 signaling pathway and may modulate insulin sensitivity. Concurrent use with insulin or insulin sensitizers could potentially affect glycemic control.
MOTS-c and other mitochondrial-derived peptides
As members of the same MDP family, co-administration of humanin with MOTS-c or SHLPs may have additive or synergistic effects on metabolic and cytoprotective pathways. No interaction data exists.
Research & benefits
Evidence base
- Evidence Level
- Preclinical only
- Total Studies
- 200+ preclinical publications
- Human Studies
- 0 completed clinical trials; observational biomarker studies only
All evidence for humanin comes from in vitro cell studies and animal models (C. elegans, mice, rats, primates). No completed human clinical trials exist as of March 2026. Observational human data shows reduced CSF humanin in Alzheimer's patients (n=3) and elevated circulating humanin in children of centenarians. Naked mole-rats maintain stable humanin levels across their lifespan, unlike mice which show ~40% decline over 18 months.
Researched for(8)
Rated by confidence in the evidence
Neuroprotection against Alzheimer's disease pathology
MediumConsistent animal and lab data show it shields neurons from Alzheimer's-related damage; no human trials yet.
PMID 23496134 (review); PMC5562564 (rat Abeta model); Biology 2023, doi:10.3390/biology12121534
Cytoprotection from apoptosis and oxidative stress
MediumIts most replicated effect, protecting many cell types from death and oxidative stress; still preclinical.
PMC10135985 (systematic review); PMC8222669 (oxidative-stress mechanism); PMID 23985350 (mitochondrial integrity)
Diabetes and insulin signaling modulation
MediumAnimal studies plus human data linking lower humanin to impaired fasting glucose; no treatment trials yet.
PMC4873641 (human impaired-fasting-glucose biomarker); PMC2709436 (Muzumdar central insulin action, PLoS ONE 2009); Frontiers Endocrinol 2021, doi:10.3389/fendo.2021.808120 (diabetes review)
Metabolic improvement and body composition
LowAnimal data suggest metabolic benefits, but body-composition effects in people remain unestablished.
PMC7343442 / PMID 32575074 (HNG healthspan, mice); PMC4873641 (human biomarker)
Cardiovascular and cellular stress protection
LowAnimal and lab studies show reduced heart injury after ischemia; no human evidence yet.
PMID 27434747 (cardiac I/R); PMC8222669 (aging CVD oxidative mechanism); PMID 23985350 (cardiac myoblasts)
Lifespan extension in model organisms
LowExtends lifespan in C. elegans; in mammals only healthspan markers, reported by one research group.
PMC7343442 / PMID 32575074 (Aging 2020, Cohen lab)
Protection against brain ischemia and traumatic brain injury
LowReduced stroke damage in mice; humanin treatment also improved cognition in a mouse traumatic brain injury model. No human treatment evidence.
PMC2575816 (cerebral I/R, PI3K/Akt); Stroke 2006, doi:10.1161/01.STR.0000242772.94277.1f
Potential protection against age-related macular degeneration
SpeculativeOnly cell-culture evidence so far; no animal or human studies in macular degeneration.
PMC5550888 (HNG AMD cybrids); PMC7767738 (RPE oxidant-injury review)
Benefits(8)
Neuroprotection against Alzheimer's disease pathology
Multiple preclinical studies in APPswe/PS1dE9 and 3xTg-AD mouse models show HNG ameliorates spatial learning/memory deficits and decreases Aβ plaque accumulation (Karachaliou & Livaniou, Biology 2023)
Cytoprotection from apoptosis and oxidative stress
Humanin inhibits Bax-mediated mitochondrial apoptosis, activates chaperone-mediated autophagy, reduces ROS, and restores mitochondrial glutathione (PMC7343442; PMC10740898)
Metabolic improvement and body composition
Mid-life HNG treatment (4 mg/kg biweekly) in 18-month-old mice decreased visceral fat, increased lean body mass, and reduced IGF-I levels (Yen et al., Aging (Albany NY) 2020, PMC7343442)
Cardiovascular and cellular stress protection
Transgenic humanin-overexpressing mice showed protection from cyclophosphamide-induced lymphocyte reduction and germ cell apoptosis (PMC7343442)
Lifespan extension in model organisms
Humanin overexpression increased C. elegans lifespan from 17.7 to 19.0 days average via daf-16/FOXO-dependent mechanism (PMC7343442)
Protection against brain ischemia and traumatic brain injury
HNG reversed cognitive impairment in mTBI models; colivelin (HN analog) decreased neurological deficits and infarct lesions in focal cerebral ischemia models (PMC10740898)
Potential protection against age-related macular degeneration
Humanin has shown cytoprotective effects in experimental models of AMD through anti-apoptotic and antioxidant mechanisms (PMC10740898)
Diabetes and insulin signaling modulation
Humanin interacts with the insulin/IGF-1 signaling pathway and has shown beneficial effects in diabetes models through IGFBP-3 binding and caspase inhibition (PMC8984571)
Key studies(7)
The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
Preclinical (C. elegans and mouse)Multiple cohorts of transgenic and wild-type animalsLifespan studiesYen K, Mehta HH, Kim SJ, et al.
Aging (Albany NY)
2020
Humanin overexpression increased C. elegans lifespan via daf-16/FOXO. In aged mice, HNG (4 mg/kg biweekly) decreased visceral fat, increased lean mass, and reduced IGF-I without extending lifespan.
Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives
Comprehensive reviewReview of 150+ studiesN/A (review)Karachaliou CE, Livaniou E
Biology (Basel)
2023
Comprehensive review of humanin's neuroprotective mechanisms including Bax inhibition, STAT3/ERK signaling, amyloid-beta interaction, and multiple analog developments. HNG is 1000-fold more potent than native humanin.
Hazafa A, Batool A, Ahmad S, Amjad M, Chaudhry SN, Asad J, Ghuman HF, Khan HM, Naeem M, Ghani U
Life Sciences
2021
Humanin protects multiple cell types from apoptosis via JAK/STAT pathway activation and BCL-2 family protein interaction. Demonstrates efficacy in models of cardiovascular disease, diabetes, and neurodegeneration.
Lee C, Yen K, Cohen P
Trends in Endocrinology & Metabolism
2013
Established humanin as the founding member of the mitochondrial-derived peptide family. Described its role as autocrine/paracrine/endocrine cytoprotective factor in cellular stress response.
Niikura T
Biochimica et Biophysica Acta – General Subjects
2021
Traced the discovery of humanin from the original 2001 screening of AD brain tissue. Described the evolution of research from neuroprotection to broad cytoprotective applications.
Humanin P3S, haplogroup N1b and the risk of Alzheimer's disease
CommentaryN/A — commentary on a separate genetic and experimental studyLogan IS, et al.
Aging Cell
2024
Identified that the mitochondrial DNA mutation m.C2639T (Humanin P3S variant) may be beneficial in people in haplogroup N1b who also carry APOE4, raising the possibility of therapeutic use of Humanin P3S in AD treatment.
Humanin, a Mitochondrial-Derived Peptide Released by Astrocytes, Prevents Synapse Loss in Hippocampal Neurons
PreclinicalIn vitro neuronal culturesAcute treatment studiesZárate SC, Traetta ME, Codagnone MG, Seilicovich A, Reinés AG
Frontiers in Aging Neuroscience
2019
Astrocyte-released humanin prevents synapse loss in hippocampal neurons, establishing a paracrine neuroprotective mechanism in the brain.
Regulation & availability
Why researchers look at it
Centenarians and their children carry significantly elevated levels of this mitochondrial peptide, while levels decline steadily with normal aging — and it was originally discovered in an Alzheimer's patient's brain tissue. A synthetic analog 1,000x more potent rescued memory in Alzheimer's mice, reduced body fat, and increased lean mass in aged animals. Separately, humanin overexpression extended lifespan in worms. All therapeutic evidence remains preclinical as of early 2026, and whether the animal findings apply to people is untested.
- FDA status
- Humanin is not FDA-approved and is not eligible for compounding in the US. No publicly confirmed IND or published human interventional treatment trial was identified. Human observational studies exist, but therapeutic efficacy and safety remain unestablished. No regulatory agency worldwide has approved humanin for any therapeutic indication.
- WADA status
- Humanin is not explicitly named on the 2026 WADA Prohibited List. As an unapproved pharmacological substance, exogenous therapeutic humanin should be treated as prohibited at all times under S0 unless another section applies. This classification follows S0's general rule and assumes no governmental approval for human therapeutic use.
- Prescribability
- No — Humanin is not FDA-approved and is not available by prescription. It remains an investigational research compound.
- Availability
- Humanin is not commercially available as a pharmaceutical product. Some peptide compounding services and wellness clinics may offer humanin or its analog HNG, but these are not regulated pharmaceutical products. The peptide can be chemically synthesized at large scale, in high yield, and at low cost, which is considered an advantage for future therapeutic development. No standardized pharmaceutical formulation exists. Administration in research settings has been via intraperitoneal, subcutaneous, intracerebral, intrahippocampal, and intranasal routes.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(9)
- 2001Discovery of Humanin from Alzheimer's disease brain tissue cDNA library by Hashimoto et al.
- 2003-2005Identification of key analogs including HNG (S14G, 1000x more potent) and Colivelin. Elucidation of CNTFR/WSX-1/gp130 trimeric receptor and STAT3 signaling.
- 2020Demonstration of lifespan extension in C. elegans and metabolic improvement in aged mice (PMC7343442).
- 2013Humanin recognized as founding member of the mitochondrial-derived peptide (MDP) family alongside MOTS-c and SHLPs (PMC3641182).
- 2019Demonstration that astrocyte-released humanin prevents synapse loss in hippocampal neurons, establishing paracrine neuroprotective mechanism.
- 2021Reviews published in Life Sciences and online in Biochimica et Biophysica Acta – General Subjects consolidate two decades of humanin research.
- 2023Major review by Karachaliou & Livaniou in Biology cataloging all humanin analogs, delivery systems, and identifying AI-assisted analog design as future direction.
- 2024Logan comments on a separate study of Humanin P3S, haplogroup N1b, longevity and APOE4-related pathology (Aging Cell).
- 2026 (current)No publicly confirmed IND or published human interventional treatment trial was identified. Observational human studies are registered. Humanin remains investigational.
Sources & FAQs
Research sources(9)
Frequently asked questions(6)
What is Humanin and where does it come from?
Humanin is a 24-amino acid peptide (sequence: MAPRGFSCLLLLTSEIDLPVKRRA) encoded by the mitochondrial genome within the 16S rRNA gene. It was first discovered in 2001 from brain tissue of an Alzheimer's disease patient. It is naturally produced by cells throughout the body and found in plasma, cerebrospinal fluid, and reproductive fluids.
How does Humanin protect cells?
Humanin works through multiple mechanisms: (1) it binds and inhibits the pro-apoptotic protein Bax, preventing cell death; (2) it activates chaperone-mediated autophagy to clear damaged proteins; (3) it reduces reactive oxygen species; (4) it signals through the CNTFR/WSX-1/gp130 receptor complex to activate STAT3; and (5) it directly interacts with amyloid-beta to prevent fibril formation.
What is HNG and how does it differ from native Humanin?
HNG (also called S14G-Humanin) is a synthetic analog where serine at position 14 is replaced with glycine. This single amino acid substitution makes HNG approximately 1000-fold more potent than native humanin in neuroprotective assays. Most animal studies use HNG rather than native humanin due to its superior efficacy.
Has Humanin been tested in humans?
No completed human clinical trials exist as of March 2026. All therapeutic evidence comes from cell culture and animal studies. However, observational human biomarker studies have shown that humanin levels in cerebrospinal fluid are reduced in Alzheimer's patients, and that children of centenarians have higher circulating humanin levels.
Does Humanin decline with aging?
Yes. Circulating humanin levels decrease with age in mice (approximately 40% decline over 18 months), monkeys, and humans. This age-related decline is associated with increased vulnerability to neurodegeneration and metabolic dysfunction. Notably, naked mole-rats — which are exceptionally long-lived — maintain stable humanin levels throughout their lifespan.
Is Humanin safe?
No formal human safety data exists. In animal studies, humanin transgenic mice showed decreased body length (12%), reduced body weight (10.4%), and reduced litter size (46.5%). A significant concern is that humanin may promote tumor growth in certain cancers, particularly triple-negative breast cancer, due to its anti-apoptotic mechanism. Community users report mild injection site reactions and occasional gastrointestinal symptoms.